Adding Custirsen to Standard of Care Did Not Improve Survival in MCRPC Patients, AFFINITY Trial Shows

Adding Custirsen to Standard of Care Did Not Improve Survival in MCRPC Patients, AFFINITY Trial Shows
Combining custirsen (OGX-011) with Jevtana (cabazitaxel) and prednisone does not improve survival of metastatic castration-resistant prostate cancer (PC) patients who progressed after prior Taxotere (docetaxel) treatment, new Phase 3 clinical data shows. The findings were included in the study, “Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *